Business Standard

Rakuten Medical trying to commercialise novel cancer therapy in India

India accounts for around 26 percent of all head and neck cancer cases globally

cancer
Premium

In India, the total number of new cancer patients in 2020 was over 1.3 million – the fourth largest population in the world

Sohini Das
US headquartered Rakuten Medical, which has recently established a subsidiary in India, is now exploring regulatory pathways to commercialize treatments based on the Alluminox platform in India, beginning with head and neck cancer.

This therapy area uses non-thermal red light to target cancer cells in the head and neck region after the patient has been administered with an injectable drug about a day back. The therapy is already approved in Japan, and Rakuten is working to get it approved by the USFDA. The company’s co-CEO Mickey Mikitan met top cancer specialists in India recently.

Abhijit Bhatia, Chief Strategy Officer, India

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in